GE healthcare stock analysis (GEHC)
GEHC with a newly FDA-approved diagnostic agent and benefits from Fed rate cuts, is considered a strong alternative and has been performing well.
Multinational investment bank and financial services company UBS downgraded GE Healthcare to Sell due to rising competition from Chinese companies.